SCHEMBL1889840

SCHEMBL1889840

CN1CCN(c2ccc(C(=O)Nc3n[nH]c4c3CN(S(=O)(=O)c3cc(F)cc(F)c3)CC4)c(NC(=O)C3CCNCC3)c2)CC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 12/20 0.74
ALK Q9UM73 17/20 0.46
INSR P06213 16/20 0.46
AURKA O14965 3/20 0.45
AURKB Q96GD4 3/20 0.45
PLK4 O00444 2/20 0.44
DAPK3 O43293 2/20 0.44
NTRK1 P04629 2/20 0.44
PRKCG P05129 2/20 0.44
ROS1 P08922 2/20 0.44
FER P16591 2/20 0.44
LTK P29376 2/20 0.44
FRK P42685 2/20 0.44
MST1R Q04912 2/20 0.44
PTK2 Q05397 2/20 0.44
TNK2 Q07912 2/20 0.44
NTRK3 Q16288 2/20 0.44
MAP4K5 Q9Y4K4 2/20 0.44
JAK2 O60674 1/20 0.44
MAP4K4 O95819 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1895600 0.97 IGF1R (0.76) IGF1RALKINSRAURKAAURKB
SCHEMBL1892331 0.96 IGF1R (0.74) IGF1RALKINSRAURKAAURKB
SCHEMBL1888080 0.96 IGF1R (0.74) IGF1RALKINSRAURKAAURKB
SCHEMBL1889997 0.95 IGF1R (0.73) IGF1RALKINSRAURKAAURKB
SCHEMBL1884528 0.94 IGF1R (0.72) IGF1RALKINSRAURKAAURKB
SCHEMBL1889897 0.93 IGF1R (0.69) IGF1RALKINSRAURKAAURKB
SCHEMBL1889644 0.92 IGF1R (0.62) IGF1RALKINSRAURKAAURKB
SCHEMBL2456315 0.92 IGF1R (0.72) IGF1RALKINSRAURKAAURKB
SCHEMBL1895260 0.91 IGF1R (0.70) IGF1RALKINSRAURKAAURKB
Hydrochloric Acid SCHEMBL2457752 0.91 IGF1R (0.71) IGF1RALKINSRAURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885ALK 517/4885INSR 922/4885
US-20090023745-A1 Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885ALK 517/4885INSR 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.